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ABSTRACT: Islet amyloid polypeptide (IAPP) is responsible for amyloid
deposition in type 2 diabetes and plays an important role in the loss of β-cell
mass associated with the disease and in the failure of islet transplants, but the
mechanism of islet amyloid formation is not understood. The incorrect
processing of proIAPP to produce partially processed forms of the peptide
has been proposed to play a role in the initiation of islet amyloid in vivo
by promoting interactions with proteoglycans of the extracellular matrix.
Insulin is a potent inhibitor of the formation of amyloid by IAPP in vitro in a
homogeneous solution; however, its ability to inhibit IAPP in the presence of
proteoglycans has not been tested, nor has its effect on the formation of amyloid
by proIAPP processing intermediates been examined. Here we show that insulin
is a much less effective amyloid inhibitor of both IAPP and proIAPP processing
intermediates in vitro in the presence of model glycosaminoglycans, but does
inhibit the formation of amyloid by proIAPP processing intermediates in a
homogeneous solution. This highlights another mechanism by which sulfated proteoglycans could enhance islet amyloid formation
in vivo. Interactions with sulfated proteoglycans can directly promote amyloid formation and can also significantly reduce the
effectiveness of natural inhibitors.
Amyloid formation is a characteristic feature of many humandiseases, including Alzheimer’s disease, Parkinson’s disease,
and type 2 diabetes.1,2 Human islet amyloid polypeptide (IAPP
or amylin) is a polypeptide hormone that forms extracellular
fibrillar amyloid deposits in the pancreatic islets of Langerhans
in type 2 diabetes.3,4 IAPP helps regulate gastric emptying,
suppression of food intake, and glucose homeostasis,5−7 but
formation of islet amyloid contributes to β-cell dysfunction in
type 2 diabetes and is associated with the decrease in β-cell mass
associated with the disease.8,9 Islet amyloid also makes important
contributions to the failure of islet transplantation.10,11 The
polypeptide is produced with insulin in the β-cells as a proform,
stored in the insulin secretory granule, and cosecreted with
insulin. Protein levels are maintained at an ∼1:100 IAPP:insulin
ratio in the secretory granule of healthy β-cells, but the con-
centration of IAPP in the granule is still much higher than that
required to promote rapid amyloid formation in vitro, suggesting
that there are factors that inhibit its aggregation in the secretory
granule. Interactions with insulin have been proposed to play
such a role in vivo and have been shown to inhibit IAPP amyloid
formation in vitro.12−14
The mechanisms of islet amyloid formation in type 2
diabetes are still not understood, although impairment of the
prohormone processing machinery has been thought to play
an important role in the initiation and progression of this
process.15−18 IAPP is synthesized as an 89-residue precursor,
preproIAPP. Removal of the signal sequence generates the
67-residue prohormone, proIAPP, which is further processed
by cleavage at two conserved dibasic sites by the same pro-
hormone convertases that process proinsulin.19 The C-terminal
prosequence is removed in either the trans-Golgi network or
secretory granule, preferentially by the prohormone convertase
PC(1/3). The remaining dibasic residues at the C-terminus
are cleaved by carboxypeptidase E (CPE),20 and amidation is
conducted by the peptidyl amidating monooxygenase complex
(PAM) with a conserved glycine residue acting as the nitrogen
donor.21 Cleavage of the prosequence at the N-terminus by
convertase PC2 gives the 37-residue mature IAPP.22 Additional
posttranslational modifications include the formation of a
disulfide between Cys2 and Cys7 (Figure 1).23
Unprocessed proinsulin and incompletely processed inter-
mediates of proinsulin are present in the early phase of type 2
diabetes,24 and the same is true for IAPP.25 Immunohisto-
chemical studies indicate the presence of the N-terminal pro-
sequence of proIAPP in islet amyloid in vivo, but not the
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C-terminal region.26,27 This suggests that incomplete process-
ing results in secretion of an intermediate peptide with the
N-terminal flanking region of proIAPP, proIAPP1−48, which
corresponds to the first 48 residues of proIAPP (Figure 1).
Two models have been proposed for how incorrectly
processed IAPP might contribute to islet amyloid formation.
One hypothesis is that the proIAPP processing intermediate
forms intragranular amyloid that causes cell death and results in
the release of amyloid that can seed extracellular formation
of amyloid by secreted mature IAPP.18 In an alternative model,
release of proIAPP1−48 leads to enhanced extracellular amyloid
formation by promoting interactions with the glycosaminogly-
can (GAG) components of heparan sulfate proteoglycans
(HSPGs) of the extracellular matrix.16,28 The HSPG perlecan
is found in islet amyloid deposits isolated from patients with
type 2 diabetes,29 and HSPGs are associated with nearly all
types of amyloid plaques.30−39 The model GAG, heparan sulfate
(HS), accelerates the formation of amyloid by both IAPP and
proIAPP1−48 in vitro.
16,40 In addition, the amyloid fibrils formed
by proIAPP1−48 in the presence of HS have been shown to
seed the formation of amyloid by IAPP in vitro, supporting
the hypothesis that proIAPP1−48 may play a role in initiating
amyloid formation.40
It is not known whether islet amyloid originates intra-
cellularly or extracellularly, and this is a controversial question.
Studies with transgenic animals that overexpress IAPP suggest
an intracellular origin, but other studies with islets have shown
that amyloid deposition is linked with secretion.41−43 In either
case, interactions with insulin could be important for inhibiting
amyloid formation in vivo, either in the granule or immediately
after release when the local concentration of IAPP and insulin
is high. Insulin is known to be an effective inhibitor of the
formation of amyloid by IAPP in vitro; however, its effect on the
formation of amyloid by proIAPP1−48 has not been investigated,
and it is possible that less effective inhibition of aggregation
by the pro form could play a role in promoting islet amyloid.
In addition, the effects of HSPGs or GAGs on the ability of
insulin to inhibit IAPP or ProIAPP1−48 amyloid formation have
not been examined. Indeed, there have been very few studies
that have examined the effectiveness of IAPP inhibitors in the
presence of sulfated proteoglycans or their GAG components.
Here we compare the ability of insulin to inhibit the formation
of amyloid by mature IAPP and the incompletely processed
intermediate proIAPP1−48. We also compare the effect of
insulin on the formation of amyloid by the two peptides in the
presence of the model GAG, HS.
■ MATERIALS AND METHODS
Peptide Synthesis and Purification. Peptides were
synthesized on a 0.25 mmol scale with an Applied Biosystems
model 433A peptide synthesizer and on a 0.1 mmol scale with a
CEM microwave peptide synthesizer utilizing 9-fluoronylme-
thoxycarbonyl (Fmoc) chemistry. Solvents were ACS-grade.
5-(4′-Fmoc-aminomethyl-3′,5-dimethoxyphenol)valeric acid
(PAL-PEG) resin was used to form an amidated C-terminus.
Fmoc-protected pseudoproline (oxazolidine) dipeptide deriva-
tives were used as previously described.44,45 Standard Fmoc
reaction cycles were used. The first residue attached to the
resin, all β-branched residues, the residues directly following
a β-branched residue, all pseudoproline dipeptide derivatives,
and the residues directly following pseudoproline dipeptide
derivatives were double-coupled for the synthesis with the Applied
Biosystems model 433A peptide synthesizer. The microwave-
assisted synthesis was performed as previously described.45
The peptides were cleaved from the resin through the use of
standard trifluoroacetic acid (TFA) methods. Crude peptides
were oxidized with dimethyl sulfoxide at room temperature.46
The peptides were purified via reverse-phase high-perform-
ance liquid chromatography (RP-HPLC) using a Vydac C18
preparative column. Analytical HPLC was used to check the
purity of the peptides before each experiment. The masses
of the pure peptides were confirmed by ionization time-of-
flight mass spectrometry: wild-type IAPP, 3902.9 (expected)
and 3902.7 (observed); proIAPP1−48, 5208.7 (expected) and
5209.4 (observed).
Sample Preparation. Peptide stock solutions were
dissolved in 100% hexafluoro-2-proponal (HFIP) at 1.6 mM.
Human insulin (recombinant, catalog no. I2643) was purchased
from Sigma. Stock solutions of insulin were first prepared by
dissolving insulin in 20 mM Tris-HCl buffer (pH 2) and then
adding dilute NaOH to adjust the pH to 7.4. Insulin solutions
were freshly made before each experiment. High-molecular
Figure 1. Processing pathway of human proIAPP. The N-terminal and C-terminal flanking regions of proIAPP are colored red. Cleavage of proIAPP occurs at
the two dibasic sites denoted with blue arrows. The C-terminal region of proIAPP is removed preferentially by PC(1/3), and the remaining dibasic residues are
removed by CPE. Final processing of the C-terminus includes removal of the remaining Gly and amidation of the Tyr by PAM, leading to the processing
intermediate proIAPP1−48. The N-terminal region is removed by PC2. There is an intramolecular disulfide bond in proIAPP1−48 and in mature IAPP.
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weight heparan sulfate (10000−14000 Da) was purchased
from Sigma. Heparan sulfate stock solutions were prepared by
dissolving HS in 20 mM Tris-HCl (pH 7.4) at a concentration
of 2.2 mg/mL.
Fluorescence Assays. Amyloid formation was monitored
by thioflavin-T binding assays without stirring at 25 °C.
Fluorescence measurements were performed using a Beckman
Coulter DTX 880 plate reader with a multimode detector with
430 nm excitation and 485 nm emission. For experiments con-
ducted in the presence of 2% HFIP, solutions were prepared by
diluting filtered stock solutions of peptides (0.45 μM Acrodisc
syringe filter with GHP membrane) in Tris-HCl buffer and a
thioflavin-T solution immediately before the measurement. For
experiments conducted without HFIP, filtered stock solutions
were first lyophilized for 22 h and then the dry peptide was
dissolved into Tris-HCl buffer and a thioflavin-T solution
immediately before the measurement. The inhibition experi-
ments were performed by first diluting peptide stock solutions
(assays with HFIP) or dissolving dry peptides (assays without
HFIP) in the buffer, followed by the addition of insulin. HS,
when present, was added last. The final conditions were 16 μM
peptide and 32 μM thioflavin-T in 20 mM Tris-HCl (pH 7.4).
HS, when present, was at a concentration of 1.3 μM.
Circular Dichroism (CD). Far-UV CD experiments were
performed at 25 °C on an Applied Photophysics Chirascan CD
spectrophotometer. Aliquots from the kinetic experiments were
removed at the end of each experiment, and the spectra were
recorded. Spectra were the average of three repeats recorded
over a range of 190−260 nm, at 1 nm intervals. A 0.1 cm quartz
cuvette was used, and a background spectrum was subtracted
from the data.
Transmission Electron Microscopy (TEM). TEM images
were collected at the Life Science Microscopy Center at the
State University of New York at Stony Brook. Aliquots (15 μL)
of the samples used for the kinetic studies were removed at the
end of each experiment, placed on a carbon-coated 300 mesh
copper grid for 1 min, and then negatively stained with saturated
uranyl acetate for 1 min.
■ RESULTS AND DISCUSSION
Insulin Inhibits the Formation of Amyloid by IAPP
and ProIAPP1−48 in a Concentration-Dependent Manner.
The ability of insulin to inhibit the formation of amyloid by
IAPP and proIAPP1−48 was tested using fluorescence-detected
thioflavin-T binding assays. These studies were conducted by
diluting solutions of the peptides solubilized in HFIP in buffer.
This is a commonly employed approach for biophysical studies
of IAPP. Additional experiments were conducted in the absence
of HFIP. Thioflavin-T experiences a significant increase in its
quantum yield upon binding to amyloid fibrils and provides
a convenient probe for monitoring the time course of fibril
formation. We first examined the formation of amyloid by
Figure 2. Inhibition of the formation of IAPP amyloid by insulin. (A)
The results of thioflavin-T binding assays are displayed. The data are
plotted as time normalized by the T50 value of IAPP in the absence of
insulin: black, IAPP; red, IAPP and insulin in a 20:1 ratio; green, IAPP
and insulin in a 40:1 ratio; blue, IAPP and insulin in a 60:1 ratio; pink,
IAPP and insulin in an 80:1 ratio; cyan, IAPP and insulin in a 100:1
ratio; brown, insulin alone at 0.8 μM. (B) TEM image of IAPP. (C)
TEM image of a 20:1 mixture of IAPP and insulin. IAPP is in 20-fold
excess. (D) TEM image of insulin alone at 0.8 μM. Aliquots were
removed at the end of each reaction for TEM analysis. Scale bars
represent 100 nm. The kinetic experiments were conducted in 20 mM
Tris-HCl (pH 7.4) and 2% (v/v) HFIP without stirring at 25 °C. The
IAPP concentration was 16 μM.
Figure 3. Inhibition of the formation of proIAPP1−48 amyloid by insulin.
(A) The results of thioflavin-T binding assays are displayed. The data are
plotted as time normalized by the T50 value of proIAPP1−48 in the
absence of insulin: black, proIAPP1−48; red, proIAPP1−48 and insulin in a
20:1 ratio; green, proIAPP1−48 and insulin in a 40:1 ratio; blue,
proIAPP1−48 and insulin in a 60:1 ratio; pink, proIAPP1−48 and insulin in
an 80:1 ratio; cyan, proIAPP1−48 and insulin in a 100:1 ratio. (B) TEM
image of proIAPP1−48. (C) TEM image of a 20:1 mixture of
proIAPP1−48 and insulin. proIAPP1−48 is in 20-fold excess. Aliquots
were removed at the end of each reaction for TEM analysis. Scale bars
represent 100 nm. The kinetic experiments were conducted in 20 mM
Tris-HCl (pH 7.4) and 2% (v/v) HFIP without stirring at 25 °C. The
proIAPP1−48 concentration was 16 μM.
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different mixtures of IAPP and insulin and observed significant
effects of insulin on the formation of amyloid by IAPP at
substoichiometric concentrations. This is consistent with prior
studies conducted in the presence of low percentages of
HFIP.13 The results, shown in Figure 2, confirm that insulin is
an effective inhibitor of the formation of amyloid by IAPP. The
data are plotted as time normalized by the T50 value of IAPP in
the absence of insulin, where T50 is the time required for the
amyloid reaction to reach 50% of the final fluorescence intensity.
The unnormalized data are included in the Supporting
Information. Insulin was still able to inhibit amyloid formation,
albeit weakly, when IAPP was in 100-fold excess, as indicated
by a 1.7-fold longer T50. The effects of insulin became more
significant as the concentration of insulin increased. In a mixture
of IAPP and insulin at a 20:1 ratio (IAPP in 20-fold excess), T50
was increased by a factor of 23 under the conditions used in
these studies. TEM images and CD spectra confirmed the
existence of fibrils with typical amyloid morphology and β-sheet
structure at the end of each reaction. This excluded the
possibility of false positives from the thioflavin-T binding assays
(Figure 2 and Supporting Information). Control experiments
conducted with insulin alone confirm that insulin did not form
amyloid in the time course of these experiments, as judged by
thioflavin-T assays and TEM (Figure 2).
The effect of insulin on the formation of amyloid by
proIAPP1−48 was also studied using this approach. An increase
in T50 was observed for all proIAPP1−48:insulin ratios tested,
and the inhibitory effect of insulin was dose-dependent.
However, insulin was less effective at inhibiting the formation
of amyloid by the processing intermediate proIAPP1−48 than by
mature IAPP under these conditions (Figure 3). For example,
when the IAPP:insulin or proIAPP1−48:insulin ratio was 20:1,
the T50 of the formation of amyloid by proIAPP1−48 was
increased 8.3-fold, while the T50 of the formation of amyloid by
IAPP was increased by a factor of 23. TEM images and CD
spectra confirmed the existence of typical fibril structure at the
end of each reaction (Figure 3 and Supporting Information).
Insulin Is a Significantly Less Effective Inhibitor in the
Presence of Heparan Sulfate. We next conducted inhibition
experiments in the presence of the model glycosaminoglycan,
HS. As expected, the formation of amyloid by IAPP was greatly
enhanced in the presence of HS, consistent with prior
reports.16,40 IAPP formed amyloid immediately after the reaction
was initiated in the presence of HS, and no lag time was
observed (Figure 4A). TEM images confirmed the presence of
amyloid fibrils, and the fibrils formed in the presence of HS had
a morphology very similar to the morphology of those formed
in the absence of HS (Figure 4). CD confirmed that β-sheet
structure was formed (Supporting Information).
Insulin was a much less effective inhibitor when HS was
present, although there were modest effects on the time required
to complete amyloid formation, and the effects of insulin were
dose-dependent. However, even at a 1:5 IAPP:insulin ratio, IAPP
formed amyloid without an apparent lag phase in the presence
of HS (Figure 4A). A rapid initial rise in fluorescence intensity
was observed followed by a more gradual rise to the final
value. Although no significant lag phase was observed, even
with relatively high concentrations of insulin (1:1 and 1:5
IAPP:insulin ratios), amyloid formation required several hours
to reach completion after the initial rapid increase in the
thioflavin-T fluorescence intensity. TEM images revealed the
presence of fibrils at the end of each experiment (Figure 4 and
Figure 4. Effects of insulin on the formation of amyloid by IAPP in the presence of HS. (A) The results of thioflavin-T binding assays are displayed.
The data are plotted as time normalized by the T50 value of IAPP in the presence of HS, but in the absence of insulin: black, IAPP in the presence of
HS; red, IAPP and insulin in a 20:1 ratio in the presence of HS; green, IAPP and insulin in a 5:1 ratio in the presence of HS; blue, IAPP and insulin
in a 1:1 ratio in the presence of HS; pink, IAPP and insulin in a 1:5 ratio in the presence of HS; brown, a mixture of 80 μM insulin and 1.3 μM HS.
(B) Expansion of the first five time units of panel A. The same color coding is used. (C) TEM image of IAPP in the presence of HS. (D) TEM image
of a 1:5 mixture of IAPP and insulin in the presence of HS. Insulin is in 5-fold excess. (E) TEM image of the insulin/HS mixture. Aliquots were
removed at the end of each reaction for TEM analysis. Scale bars represent 100 nm. The kinetic experiments were conducted in 20 mM Tris-HCl
(pH 7.4) and 2% (v/v) HFIP without stirring at 25 °C. The IAPP concentration was 16 μM. The HS concentration was 1.3 μM.
Biochemistry Article
dx.doi.org/10.1021/bi4015488 | Biochemistry 2014, 53, 2605−26142608
Supporting Information). Similar behavior has been observed
in experiments using other inhibitors in the presence of HS and
has been proposed to be due to the rapid formation of a GAG−
peptide intermediate.47 CD spectra of mixtures with a low con-
centration of insulin showed typical β-sheet structure, while
those from samples with a higher concentration of insulin (1:1
and 1:5 IAPP:insulin ratios) exhibited a broad peak centered at
219 nm, likely due to contributions from the insulin α-helical
structure (Supporting Information). Interestingly, in the
presence of HS, the CD signal of either IAPP or mixtures of
IAPP and insulin appears to be more intense than in the absence
of HS (Supporting Information). This may be caused by the fact
that HS has a solubilizing effect on the aggregates formed so they
are less prone to bind to the walls of the microplates or segregate
to the air−water interface or pellet. The exact reason for the
differencies in the intensity of the CD spectra is not clear, but
the shape of the spectrum reports on the secondary structure of
the soluble aggregates.
Insulin is also much less effective at inhibiting the formation
of amyloid by proIAPP1−48 in the presence of HS (Figure 5).
Insulin barely showed any inhibitory effect at 20:1 and 5:1
proIAPP1−48:insulin ratios in the presence of HS. Increasing the
amount of insulin to a ratio of 1:1 and 1:5 slightly increased
the time required to complete amyloid formation, but no lag
time was observed. TEM images and CD spectra confirmed the
results of thioflavin-T fluorescence and showed that amyloid
was formed (Supporting Information).
Insulin is able to aggregate; thus, to exclude the possibility
that the results discussed above were caused by interactions
of insulin with HS, we monitored the thioflavin-T fluorescence
of a mixture of insulin and HS. No increase in fluorescence was
observed during the time course of the study (Figure 4A),
and TEM showed that no fibrils were formed (Figure 4E).
The CD spectrum revealed helical structure that is similar to
that observed from insulin samples that did not contain HS
(Supporting Information).
The Observed Effects Are Not Due to the Presence of
Organic Cosolvents. The results outlined above were
collected using assays with 2% HFIP by volume as a cosolvent.
Even this low percentage of organic solvent accelerates the
kinetics of the formation of amyloid by IAPP significantly.48,49
Initial kinetic studies of the effects of insulin on IAPP amyloid
formation made use of HFIP as a cosolvent,13 and subsequent
studies showed that similar relative effects were obtained in
the absence of HFIP in many cases.50 We compared the ability
of insulin to inhibit the formation of amyloid by both IAPP
and proIAPP1−48 in the absence and presence of HS using
a different assay that avoided the use of HFIP to exclude the
possibility that our results were a consequence of the condi-
tions used. Control experiments conducted with insulin in the
absence of HFIP or IAPP showed that it did not form amyloid
under these conditions during the time course of the experi-
ments (Supporting Information). The results showed that in
the absence of HFIP, at a 1:20 ratio (IAPP is in 20-fold excess),
insulin increased the T50 of the formation of amyloid by IAPP
by a factor of 3.3 in a homogeneous solution (Figure 6A). For
comparison, insulin at the same ratio increased the T50 of the
formation of amyloid by IAPP by a factor of 23 in the presence
of HFIP. The reason for the proportionally larger effect in
HFIP is not clear but may reflect the acquisition of structure in
HFIP that facilitates interactions of IAPP with insulin. Peptide
mapping studies have suggested that the region corresponding
Figure 5. Effects of insulin on the formation of amyloid by proIAPP1−48 in the presence of HS. (A) The results of thioflavin-T binding assays are
displayed. The data are plotted as time normalized by the T50 value of proIAPP1−48 in the presence of HS, but in the absence of insulin: black,
proIAPP1−48 in the presence of HS; red, proIAPP1−48 and insulin in a 20:1 ratio in the presence of HS; green, proIAPP1−48 and insulin in a 5:1 ratio
in the presence of HS; blue, proIAPP1−48 and insulin in a 1:1 ratio in the presence of HS; pink, proIAPP1−48 and insulin in a 1:5 ratio in the presence
of HS. (B) Expansion of the first five time units of panel A. The same color coding is used. (C) TEM image of proIAPP1−48 in the presence of HS.
(D) TEM image of a 1:5 mixture of proIAPP1−48 and insulin in the presence of HS. Insulin is in 5-fold excess. Aliquots were removed at the end of
each reaction for TEM analysis. Scale bars represent 100 nm. The kinetic experiments were conducted in 20 mM Tris-HCl (pH 7.4) and 2% (v/v)
HFIP without stirring at 25 °C. The proIAPP1−48 concentration was 16 μM. The HS concentration was 1.3 μM.
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to residues 7−19 of IAPP interacts with insulin. This segment
of IAPP has been proposed to form a transient helical structure
during amyloid formation,51−55 and even low levels of HFIP
can promote helical structure.
When HS was present, the formation of amyloid by IAPP
was greatly accelerated, as indicated by the lack of a lag phase.
In addition, insulin was a much less effective inhibitor of
the formation of amyloid by IAPP in the presence of HS
(Figure 6B). At a 20:1 IAPP:insulin ratio, the time required to
complete the formation of amyloid by IAPP was increased by a
factor of only 1.3 when HS was in the mixture. These results are
consistent with the trends observed in the presence of HFIP
and indicate that the observations are not an artifact caused by
residual HFIP. TEM images were collected at the end of each
experiment and confirmed that amyloid was formed (Figure 6).
Very similar results were obtained with proIAPP1−48. In the
absence of HFIP, insulin increased the T50 of the formation
of amyloid by proIAPP1−48 by 2.7-fold when proIAPP1−48
and insulin were in a 20:1 ratio in a homogeneous solution
(Figure 7A). In contrast, at the same proIAPP1−48:insulin ratio,
T50 was increased by a factor of 8.3 in the presence of HFIP.
We also tested the ability of insulin to inhibit the formation
of amyloid by proIAPP1−48 in the presence of HS, but in the
absence of HFIP. Insulin is a much less effective inhibitor of
the formation of amyloid by proIAPP1−48 when HS is present.
In the presence of HS, proIAPP1−48 immediately aggregated to
form amyloid fibrils without any observable lag phase. The time
required to complete the formation of amyloid by proIAPP1−48
in the presence of insulin is nearly the same as that without
insulin (Figure 7B). TEM images were collected at the end
of each experiment and confirmed that amyloid was formed
(Figure 7).
■ CONCLUSIONS
The data show that insulin is a potent amyloid inhibitor for
both IAPP and the proIAPP1−48 processing intermediate in
homogeneous solutions. Figure 8 shows a comparison of the
ability of insulin to inhibit the formation of amyloid by IAPP
and proIAPP1−48 as judged by the T50 values in the presence of
HFIP. Insulin, at relatively high concentrations, is more potent in
slowing the formation of amyloid by IAPP than by proIAPP1−48,
and the inhibition of the formation of IAPP amyloid by insulin
is more sensitive to changes in the insulin level than is the
inhibition of the formation of amyloid by proIAPP1−48. For
example, a 5-fold change in insulin concentration in the mixture
(IAPP:insulin ratio ranging from 100:1 to 20:1) led to a
significant increase in the T50 of the formation of amyloid by
IAPP, from 1.7- to 23-fold relative to that with IAPP alone. In
contrast, increasing the insulin ratio by the same amount had a
smaller effect on proIAPP1−48; T50 increased from 2.7- to 8.3-fold
relative to that with proIAPP1−48 alone. However, insulin is still
an effective inhibitor, arguing that interactions between
proIAPP1−48 and insulin that are weaker than those between
IAPP and insulin are unlikely to account for islet amyloid
formation in vivo.
The effects of insulin on the formation of amyloid by IAPP
and proIAPP1−48 in the presence of HS are quantitatively
compared in terms of T50 in Figure 9. The ability of insulin to
inhibit amyloid formation is greatly weakened in the presence
Figure 6. Inhibition by insulin of the formation of amyloid by IAPP in the presence and absence of HS in buffer without HFIP. (A) Inhibition in the
absence of HS monitored by thioflavin-T assays: black, IAPP; red, IAPP and insulin in a 20:1 ratio. Data are plotted as time normalized by the T50
value of IAPP in the absence of insulin. (B) Inhibition in the presence of HS monitored by thioflavin-T assays. Data are plotted as time normalized
by the T50 value of IAPP in the presence of HS, but in the absence of insulin. The same color coding is used here as in panel A. (C) TEM image of
IAPP in the absence of HS. (D) TEM image of a 20:1 mixture of IAPP and insulin in the absence of HS (IAPP was in 20-fold excess). (E) TEM
image of IAPP in the presence of HS. (F) TEM image of a 20:1 mixture of IAPP and insulin in the presence of HS (IAPP was in 20-fold excess).
Scale bars represent 100 nm. Aliquots were removed at the end of each experiment for TEM analysis. The kinetic experiments were conducted in
20 mM Tris-HCl (pH 7.4) without stirring at 25 °C. The IAPP concentration was 16 μM. The HS concentration was 1.3 μM (when present).
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of HS for both peptides. When peptide and insulin are
combined at a 20:1 ratio, the T50 for the formation of amyloid
by IAPP is increased by a factor of only 1.6, and no obvious
increase in T50 is observed for proIAPP1−48. Even at the highest
concentrations of insulin (1:1 and 1:5 ratios of IAPP or
proIAPP1−48 to insulin), T50 is increased by <3-fold for both
peptides in the presence of HS. The formation of amyloid by
IAPP is slightly more effectively inhibited than is the formation
of amyloid by proIAPP1−48 in the presence of HS. However,
insulin is clearly a significantly worse inhibitor of the formation
of amyloid by either peptide in the presence of HS.
Figure 8. Bar graph comparing the T50 values for the formation of
amyloid by IAPP and proIAPP1−48 in the presence of 2% HFIP at
different ratios of IAPP or proIAPP1−48 to insulin: black bars, mixtures
of IAPP and insulin; gray bars, mixtures of proIAPP1−48 and insulin.
Values of T50 were derived from the kinetic curves shown in Figures 2
and 3. Data are plotted as T50 normalized by the value of T50 of either
IAPP or proIAPP1−48 in the absence of insulin. Experiments were
conducted in 20 mM Tris-HCl (pH 7.4) and 2% (v/v) HFIP without
stirring at 25 °C. The IAPP or proIAPP1−48 concentration was 16 μM.
Figure 9. Bar graph comparing the T50 values for amyloid formation in
buffer with HFIP for mixtures of IAPP with insulin and for mixtures of
proIAPP1−48 with insulin in the presence of HS. Values are plotted for
different ratios of IAPP or proIAPP1−48 to insulin: black bars, mixtures
of IAPP and insulin in the presence of HS; gray bars, mixtures of
proIAPP1−48 and insulin in the presence of HS. The data are plotted as
T50 normalized by the T50 value of either IAPP or proIAPP1−48 in the
presence of HS, but in the absence of insulin. Values of T50 were
derived from the kinetic curves in Figures 4 and 5. Experiments were
conducted in 20 mM Tris-HCl (pH 7.4) and 2% (v/v) HFIP without
stirring at 25 °C. The IAPP or proIAPP1−48 concentration was 16 μM.
The HS concentration was 1.3 μM.
Figure 7. Inhibition by insulin of the formation of amyloid by proIAPP1−48 in the presence and absence of HS in buffer without HFIP. (A) Inhibition
in the absence of HS monitored by thioflavin-T assays. Data are plotted as time normalized by the T50 value of proIAPP1−48 in the absence of insulin:
black, proIAPP1−48; red, proIAPP1−48 and insulin in a 20:1 ratio. (B) Inhibition in the presence of HS monitored by thioflavin-T assays. Data are
plotted as time normalized by the T50 value of proIAPP1−48 in the presence of HS, but in the absence of insulin. The same color coding is used here as
in panel A. (C) TEM image of proIAPP1−48 in the absence of HS. (D) TEM image of a 20:1 mixture of proIAPP1−48 and insulin in the absence of HS.
(E) TEM image of proIAPP1−48 in the presence of HS. (F) TEM image of a 20:1 mixture of proIAPP1−48 and insulin in the presence of HS. Scale bars
represent 100 nm. Aliquots were removed at the end of each experiment for TEM analysis. The kinetic experiments were conducted in 20 mM Tris-
HCl (pH 7.4) without stirring at 25 °C. The proIAPP1−48 concentration was 16 μM. The HS concentration was 1.3 μM (when present).
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Our control experiments show that the results are not due to
the presence of HFIP. Insulin is a much less effective inhibitor
of amyloid formation in the presence of HS even in the absence
of HFIP. The results are summarized in Figure 10. The T50 for
the formation of amyloid by IAPP and proIAPP1−48 in the
absence of HFIP is increased by 3.3- and 2.7-fold, respectively, at a
20:1 ratio of IAPP or proIAPP1−48 to insulin in a homogeneous
solution. However, in the presence of HS, insulin, at the same ratio,
increased the time required for the formation of amyloid by IAPP
by a factor of only 1.3, while the kinetics of the formation of
amyloid by proIAPP1−48 was virtually unaltered. No lag phase was
observed for the formation of amyloid by either IAPP or
proIAPP1−48 even at a 20:1 ratio of IAPP or proIAPP1−48 to insulin.
HS is not the only factor that can accelerate the formation of
amyloid by IAPP. Anionic vesicles also catalyze the formation
of amyloid by IAPP. Insulin still inhibits the process in the
presence of anionic model membranes;50,56 however, insulin is
noticeably less effective.50 Those studies together with this work
highlight the importance of considering the role of the hetero-
geneous environment in amyloid formation. The deleterious
effects of HS on insulin’s ability to act as an amyloid inhibitor
could be due to stronger interactions of IAPP or proIAPP1−48
with HS than with insulin. Alternatively, HS might bind to
insulin and sequester the inhibitor, or both effects could play a
role. The data presented here clearly show that HS accelerates
the formation of amyloid by proIAPP1−48 and IAPP, and this
has been established to occur via direct interactions between the
peptides and the GAG.47,57 These observations, along with the
fact that HS did not induce the formation of amyloid by insulin
under the conditions used in our studies, suggest that inter-
actions between IAPP or proIAPP1−48 and HS outcompete
interactions between insulin and IAPP or proIAPP1−48.
Our observations suggest another mechanism by which HS
can promote amyloid formation. Proteoglycans can accelerate
amyloid formation by direct interactions with proIAPP1−48 or
IAPP and can also significantly reduce the inhibitory effects
of insulin.
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